About this item:

438 Views | 893 Downloads

Author Notes:

N. K. Wenger: Email: nwenger@emory.edu and S. J. Lewis: Email: sandral@nw-ci.com

Academic Editor: Thomas M. Stulnig

Dr. Wenger has been a member of clinical trial steering committees or received research support from Pfizer, Merck, NHLBI, Gilead Sciences (formerly CV Therapeutics), Abbott, Sanofi-Aventis and Eli Lilly.

She has also acted as a consultant for Gilead Sciences, Schering-Plough, Astra Zeneca, Abbott, Merck, Pfizer, Boston Scientific, Medtronic, and Genzyme.

Dr. Lewis has received research support from Pfizer, AstraZeneca and Roche.

She has also acted as a consultant for AstraZeneca and Pfizer.


Research Funding:

Editorial support was provided by Paul Lane and Iain Patten of UBC Scientific Solutions and funded by Pfizer Inc.

Dr. Lewis has received research support from Pfizer, AstraZeneca and Roche.

Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients


Journal Title:

Current Gerontology and Geriatrics Research


Volume 2010, Number 2010


, Pages 1-10

Type of Work:

Article | Final Publisher PDF


Background. Cardiovascular disease is the principal cause of mortality in older individuals, and more than 80% of deaths due to coronary heart disease or stroke occur in patients over 65 years of age. Hyperlipidemia is one of the main modifiable risk factors for cardiovascular disease. Current guidelines recommend the use of statins to reduce low-density lipoprotein cholesterol to appropriate targets based on an individual's cardiovascular risk, and clearly state that older age should not be a barrier to treatment. Despite extensive evidence demonstrating clear benefit with statin therapy in older individuals, this population remains chronically undertreated. Scope. This paper provides an overview of the current evidence available regarding the efficacy and safety of statin therapy to reduce cardiovascular risk in older patients. We use hypothetical case studies to address some of the questions frequently posed by physicians responsible for the cardiovascular health of older patients. Conclusions. Various factors may account for the failure to provide appropriate treatment, including a lack of awareness of clinical benefits and perceived safety issues. However, if current guidelines are followed and older patients treated to appropriate LDL-C goals, the likelihood of cardiovascular events will be reduced in this high-risk population. Employing an evidence-based approach to the management of cardiovascular risk in older patients is likely to yield benefits in terms of overall cardiovascular burden.

Copyright information:

© 2010 N. K. Wenger and S. J. Lewis

This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Creative Commons License

Export to EndNote